Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression.
- Conditions
- EsophagitisMetastatic Spinal Cord CompressionRadiation ToxicityPatient Reported Outcome Measures
- Interventions
- Radiation: Esophagus sparring radiotherapy treatment
- Registration Number
- NCT05109819
- Lead Sponsor
- Herlev Hospital
- Brief Summary
Metastatic spinal cord compression (MSCC) is a serious complication to metastatic cancer and when diagnosed life expectancy is short. Treatment is palliative radiotherapy (RT). Early esophageal toxicity is underreported but can seriously impact quality of life (QoL).
The aim of the ESO-SPARE trial is to investigate if esophagus sparing RT can decrease patient reported esophageal toxicity without compromising ambulatory function or increase other toxicities.
200 patients with MSCC in the thoracic or cervical spine referred for RT will be randomized to either standard or esophagus/pharynx sparing RT. Subsequently participants will be followed with PROM (Patient Reported Outcome Measures) for 9 weeks. PROM-CTCAE questionnaires on upper GI toxicity and pain will be collected daily for 5 weeks and weekly for 4 weeks. Questionnaires evaluating QoL and physical function will be collected weekly for 9 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
-
Histology or cytology proven cancer
-
Referred for palliative radiotherapy of the cervical or thoracic vertebra for
- epidural ingrowth
- metastatic spinal cord compression
- metastatic spinal nerve root compression
- post-operative radiotherapy after decompressive surgery for spinal cord or nerve root compression
-
Ability to understand and the willingness to sign a written informed consent document
-
Referred for the following dose prescriptions 5 Gy x 5, 5 Gy x 4, 3 Gy x 10, 10 Gy x 1, 8 Gy x 1.
-
≥ 18 years old.
- Referred for > 10 fractions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B: esophagus sparring radiotherapy treatment Esophagus sparring radiotherapy treatment Patients in arm B will receive esophagus sparring radiotherapy treatment.
- Primary Outcome Measures
Name Time Method Ambulatory function Measured 9 weeks after treatment start Preserved ability to walk will be evaluated using the European Quality of Life - 5 Dimensions questionnaire (EQ-5D-5L) mobility dimension. The EQ-5D includes one question for each of the five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5).
Early patient reported gastro-oesophageal toxicity Measured within the first 5 weeks after treatment start Measured as a peak score using CTCAE Patient Reported Outcome Measures
- Secondary Outcome Measures
Name Time Method Analgesic consumption Assessed Weekly over a period of 9 weeks Assessed Weekly over a period of 9 weeks
Pain assessment (MTS site) Best response during 9 weeks of follow-up Assessment will be performed using International Consensus Pain Response Endpoints (ICPRE).
* A complete pain response is defined as a pain score of 0 out of 10 at the treated site with no concomitant increase in analgesic intake
* A partial pain response is defined as a pain reduction of 2 or more at the treated site without analgesic increase, or an analgesic reduction of 25% with no increase in pain score or 1 point above baseline.
* Pain progression is defined as an increase in pain score of 2 or more above baseline with stable analgesic intake or an analgesic increase of 25% with stable pain score.
* An indeterminate response is any response not captured in the above definitions.
Analysis of pain reduction will only include patients with NPRS ≥ 1 registered at baseline. We intend to report the best response during follow-up.Duration of gastro-oesophageal toxicity Assessed 9 weeks after treatment start Measured as the time from an increase in gastro-oesophageal symptom score to a return to baseline
Reirradiation rate - Overall survival (OS) Assessed 6 months after inclusion of the last patient. Defined as fraction of patients getting reirradiation, where the same spine levels are included in the irradiated volume
Patient reported physical function Assessed Weekly over a period of 9 weeks Patient reported physical function will be assessed using answers from the EORTC QLQ-C30 questionnaire. Questions regarding physical function are measured on a four-point scale (1= not at all, 2 = a little, 3 = quite a bit, 4 = very much). All EORTC QLQ-C30 answers will be scored according to the EORTC QLQ-C30 Scoring Manual.
Health related Quality of life (QoL) Assessed Weekly over a period of 9 weeks Health related quality of life assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire - Cancer (QLQ-C30). The EORTC QLQ-C30 consists of 30 questions assessing quality of life issues using a four-point scale (1= not at all, 2 = a little, 3 = quite a bit, 4 = very much) except from the last two questions which are measured between 1 (Very Poor) to 7 (Excellent). The EORTC QLQ-C30 will be scored according to the EORTC QLQ-C30 Scoring Manual.
Weight Assessed Weekly over a period of 9 weeks Assessed Weekly over a period of 9 weeks
Pain (MSCC site) Assessed daily for 5 weeks and subsequently weekly for 4 weeks. Evaluated by "Numeric Pain Rating Scale (NPRS)"
The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).
Trial Locations
- Locations (2)
Rigshospitalet
🇩🇰Copenhagen, Denmark
Herlev Hospatal
🇩🇰Herlev, Denmark